MARKET STRUCTURE · COMPETITIVE · INDIA
Zydus and Lupin sign deal to co‑market semaglutide injections
Change
Zydus Lifesciences and Lupin signed a licensing and supply deal on March 17 to co‑market semaglutide injections in India.
Why it matters
Lupin received semi‑exclusive rights to co‑market semaglutide under the brand names Semanext and Livarise. Lupin will pay Zydus upfront licensing fees and milestone‑based payments. Zydus will manufacture the product at its Ahmedabad facility in Gujarat and market it under the brand names Semaglyntm, Mashematm and Alterme. Zydus's single‑adjustable pen allows patients to select different doses, and Zydus received regulatory approval in January to make and sell generic versions of the weight‑loss drugs.
Implications
- · Lupin's commercial activity for semaglutide is constrained to semi‑exclusive co‑marketing under specified brand names.
- · Zydus is obligated to manufacture semaglutide at its Ahmedabad facility and to market under the specified Zydus brand names.
- · Lupin is contractually obligated to provide upfront licensing fees and milestone‑based payments to Zydus.
- · Product supply will be delivered using a single‑adjustable pen format that permits dose selection rather than multiple single‑use pens.
Who is affected
- · Pharmaceutical manufacturers
- · Commercial and marketing teams
- · Supply chain and manufacturing operations
- · Regulatory affairs teams
Source
Topics
Business & Markets Supply Chain & Logistics Health & Medicine Pharma & Biotech